{"version":"1.0","type":"link","title":"Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.","author_name":"Reck M 외","author_url":"https://prs-insight.online/author/Reck%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/100730","thumbnail_width":1200,"thumbnail_height":630}